Anebulo Shares Gain After Positive Topline Results From Mid-stage Study Of Cannabinoid Intoxication Candidate

Anebulo Pharmaceuticals ANEB announced positive topline data from Part A of an ongoing Phase 2 clinical trial of its drug candidate  ANEB-001 for patients with acute cannabinoid intoxication (ACI).

The Part A portion of Phase 2 study evaluated effectiveness of a single dose of ANEB-001 in treating healthy subjects challenged with delta-9-tetrahydrocannabinol.

Simon Allen, Chief Executive Officer, commented : "We believe this proof-of-concept trial demonstrates ANEB-001's potential to reverse the symptoms of ACI for many of the five thousand cannabinoid intoxicated individuals visiting our emergency departments in the United States on a daily basis.”

The study was conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and enrolled 60 healthy adult occasional cannabis users to three treatment arms of 20 subjects per arm.

With the positive data readout from Part A study, Anebulo plans to initiate Part B of the study by the end of third quarter 2022 to evaluate lower doses of ANEB-001.

The company is planning to submit an Investigational New Drug application (IND) for ANEB-001 to initiate clinical trials in the United States by the end of 2022.

Anebulo shares are trading higher 21 percent at $6.50 during Tuesday’s pre-market session.

Posted In: Topline ResultsBiotechHealth CareMovers & ShakersGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.